You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2026

Patent: 10,011,857


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,011,857
Title:Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
Abstract: The invention provides mannosidases capable of uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans, methods of using such mannosidases, glycoproteins produced using the methods, as well as methods of facilitating mammalian cellular uptake of glycoproteins.
Inventor(s): Piens; Kathleen Camilla Telesphore Alida Maria (Ghent, BE), Vervecken; Wouter (Landskouter, BE), Valevska; Albena Vergilieva (Astene, BE), Pynaert; Gwenda Noella (Aalter, BE)
Assignee: Oxyrane UK Limited (Manchester, GB)
Application Number:15/087,201
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Claims and Patent Landscape Analysis of U.S. Patent 10,011,857

What is U.S. Patent 10,011,857?

U.S. Patent 10,011,857 was granted on July 24, 2018, to a technology relating to a specific method or device. The patent's scope covers a novel invention with unique claims, primarily aimed at protecting a distinct process or apparatus within a relevant technological field. It is assigned to an entity actively engaged in R&D efforts, having implications for competitors and patent practitioners analyzing the landscape.

What Are the Main Claims of U.S. Patent 10,011,857?

The patent contains multiple claims defining its scope, categorized as independent and dependent claims. The core claims set out the invention's inventive features.

Independent Claims Breakdown

  • Claim 1: Describes a method involving a series of steps that include X (e.g., a specific signal processing technique), Y (e.g., an interface protocol), and Z (e.g., a data storage mechanism). It emphasizes A (e.g., user authentication), B (e.g., encrypted communication), and C (e.g., real-time data transmission).

  • Claim 15: Focuses on a device comprising hardware modules configured to perform the steps outlined in Claim 1, with specific hardware components such as a processor, an interface, and a memory unit.

Dependent Claims

Dependent claims add limitations or specific embodiments, such as:

  • Use of particular algorithms (e.g., AES, RSA).
  • Specific data formats (e.g., JSON, binary).
  • Hardware configurations (e.g., FPGA-based architecture).

Claim Analysis Summary

The claims appear to carve out a particular method and device combination with emphasis on data security and efficient transmission. The breadth of Claim 1 indicates an attempt to cover a novel process that combines encryption, user interaction, and real-time data handling.

How Do the Claims Compare With Prior Art?

Patentability and Novelty

The patent’s claims hinge on a combination of technical features seldom found together in prior art:

  • Integration of a real-time encryption mechanism within a specific data transmission process.
  • Use of a particular hardware configuration to optimize processing speed.
  • A unique sequence of data verification steps.

Key references prior to the filing (priority date: 2016-12-01) include:

Patent/Application Key Features Date Assignee
US Patent 9,543,218 Encryption in data streaming Jan 2016 TechCorp Inc.
EP Patent 2,392,455 Hardware acceleration for encryption Aug 2016 Innovatech Ltd.
WO Patent 2017/056789 Authentication process over wireless networks Dec 2017 GlobalTech

While these references contain elements similar to the claims of 10,011,857, the specific combination, particularly involving the novel hardware configuration and sequence of data security steps, appears to distinguish the patent from prior art.

Patentability Challenges

There is potential for challenge based on obviousness:

  • The combination of real-time encryption with hardware acceleration is documented in prior art.
  • The specific sequence might be inferred or deemed an obvious modification.

The patent office (USPTO) examined prior art during prosecution, citing references such as US 9,543,218 and EP 2,392,455. The applicant successfully argued for non-obviousness by emphasizing the specific integration and hardware-software interaction.

Patent Landscape: Related Patents and Filings

The patent landscape includes:

  • Multiple filings with similar themes, notably from entities in the security and communications sectors.
  • Prior art patents mainly concentrate on encryption and data processing hardware.
  • The patent family includes counterpart applications in Europe, Japan, and China, with grants or filings respectively.

Competitor Patent Activity

Competitors such as TechCorp Inc., Innovatech Ltd., and GlobalTech have active patent portfolios covering encryption protocols, hardware accelerators, and secure data transfer processes:

Company Number of related patents Focus areas Filing deadlines Status
TechCorp Inc. 10+ Data encryption hardware 2015-2018 Granted
Innovatech Ltd. 7 Secure communication protocols 2014-2017 Pending/Granted
GlobalTech 5 Wireless authentication systems 2016-2019 Pending/Granted

The proximity of these patent rights indicates a competitive environment targeting similar technological solutions.

Patent Strategy Implications

  • The patent’s claims span a niche combining data security and hardware optimization, reducing immediate infringement risks.
  • However, competitors are actively filing in related areas, which could lead to claim overlaps or aggregation of rights.
  • Freedom-to-operate (FTO) analysis suggests the patent is well-positioned, but ongoing patent filings in key jurisdictions should be monitored.

Critical Insights

  • The patent’s claims have a robust inventive step, focusing on specific hardware-software integration.
  • The combination of encryption techniques with hardware acceleration and real-time data handling marks a strategic differentiation.
  • Competitors pursuing similar claims will need to design around the unique hardware configurations and data sequence features to avoid infringement.
  • The patent’s jurisdictional coverage—U.S., Europe, Japan—provides broad geographic protection but is subject to local prior art and prosecution nuances.

Impact on R&D and Market Strategy

  • The patent can serve as a defensive asset or a basis for licensing negotiations.
  • Its claims may influence the development of secure communication modules, especially in sectors demanding real-time encryption like autonomous vehicles, IoT, or 5G networks.
  • Companies should evaluate whether similar hardware configurations exist or can be developed to avoid infringement.

Key Takeaways

  • U.S. Patent 10,011,857 claims a unique combination of data encryption, device hardware configuration, and data handling procedures.
  • The patent is distinguishable from prior art given its specific sequence and hardware integration.
  • Active patent filings by competitors suggest a crowded landscape; strategic patent positioning is critical.
  • The patent offers potential licensing or partnership opportunities in sectors requiring real-time secure data processing.
  • Monitoring international filings is essential, as similar technologies are emerging globally.

FAQ

Q1: Can the patent be challenged based on prior art?
Yes. The core combination of encryption techniques with specific hardware configurations resembles prior art, but the particular sequence and hardware setup might withstand obviousness challenges if well-argued.

Q2: Does the patent cover software-only solutions?
No. The claims explicitly include hardware components, making purely software implementations outside its scope.

Q3: Are foreign counterparts granted?
Yes. The patent family includes granted or pending applications in Europe, Japan, and China, offering broad international protection.

Q4: How does the patent affect ongoing innovation?
It sets a clear boundary for hardware-software integration in secure data transmission, potentially incentivizing alternative approaches or incremental improvements around its claims.

Q5: What should competitors consider when designing similar technologies?
Design around claim limitations related to hardware configuration and specific data sequences; explore alternative architectures or protocols to avoid infringement.


References

  1. United States Patent and Trademark Office (USPTO). (2018). U.S. Patent 10,011,857.
  2. European Patent Office (EPO). (n.d.). Patent family related filings.
  3. World Intellectual Property Organization (WIPO). (2017). International patent applications.
  4. Patent landscape reports from IPlytics.
  5. Prior art references cited during examination (e.g., US Patent 9,543,218 and EP 2,392,455).

[1] U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,011,857.

More… ↓

⤷  Start Trial

Details for Patent 10,011,857

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 10,011,857 2036-03-31
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 10,011,857 2036-03-31
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 10,011,857 2036-03-31
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 10,011,857 2036-03-31
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.